Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: A systematic review and meta-analysis

The Lancet Infectious Diseases

Volumn 15, Issue 7, 2015, Pages 819-824

  Rao, V Bhargavi ^a,b   Johari, Nur ^b   du Cros, Philipp ^a   Messina, Janey ^d   Ford, Nathan ^a,b,c   Cooke, Graham S ^b  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICA SOUTH OF THE SAHARA; ARTICLE; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; META ANALYSIS; MIXED INFECTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEROPREVALENCE; SYSTEMATIC REVIEW; WORLD HEALTH ORGANIZATION; COINFECTION; HIV INFECTIONS;

AFRICA SOUTH OF THE SAHARA; COINFECTION; HEPATITIS C; HIV INFECTIONS; HUMANS; PREVALENCE; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES;

EID: 84938983484     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00006-7     Document Type: Article

References (26)

1. Hepatitis C. 2015 WHO, (accessed March 3, 2015). http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index4.html.
2. Lavanchy D Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011, 17:107-115.
3. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
4. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014, 370:1604-1614.
5. Ford N, Kirby C, Singh K, et al. Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis. Bull World Health Organ 2012, 90:540-550.
6. Ford N, Singh K, Cooke GS, et al. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis 2012, 54:1465-1472.
7. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013, 368:1867-1877.
8. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med; 368: 34-44.
9. Casey LC, Lee WM Hepatitis C therapy update. Curr Opin Gastroenterol 2012, 28:188-192.
10. Welsch C, Jesudian A, Zeuzem S, Jacobson I New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 2012, 61(suppl 1):i36-i46.
11. Callaway E Hepatitis C drugs not reaching poor. Nature 2014, 508:295-296.
12. Davies A, Singh KP, Shubber Z, et al. Treatment outcomes of treatment-naive Hepatitis C patients co-infected with HIV: a systematic review and meta-analysis of observational cohorts. PLoS One 2013, 8:e55373.
13. Madhava V, Burgess C, Drucker E Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis 2002, 2:293-302.
14. Barth RE, Huijgen Q, Taljaard J, Hoepelman AI Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis 2010, 14:e1024-e1031.
15. DerSimonian R, Laird N Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
16. Borenstein M, Hedges L, Higgins J, Rothstein H A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Meth 2010, 1:97-111.
17. Freeman M Transformations related to the angular and the square root. Ann Inst Stat Mathematics 1950, 21:607-611.
18. Newcombe RG Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998, 17:857-872.
19. Newcombe RG Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998, 17:873-890.
20. Reddy R, Vermeulen M, Lelie N, et al. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa. Transfusion 2009, 49:1115-1125.
21. Opaleye OO, Zakariyahu TO, Tijani BA, Bakarey AS HBV, HCV co-infection among blood donors in Nigeria. Indian J Pathol Microbiol 2010, 53:182-183.
22. Muasya T, Lore W, Yano K, et al. Prevalence of hepatitis C virus and its genotypes among a cohort of drug users in Kenya. East African Med J 2008, 85:318-325.
23. Global report: UNAIDS report on the global AIDS epidemic 2013 UNAIDS, (accessed March 3, 2015). http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf.
24. Rorat M, Jurek T, Szleszkowski L, Gladysz A Outbreak of hepatitis C among patients admitted to the Department of Gynecology, Obstetrics, and Oncology. Am J Infect Control 2014, 42:e7-10.
25. Muir D, Chow Y, Tedder R, Smith D, Harrison J, Holmes A Transmission of hepatitis C from a midwife to a patient through non-exposure prone procedures. J Med Virol 2014, 86:235-240.
26. Cadranel JF, Di Martino V, Lambrey G, et al. Prevalence of hepatitis C infection and risk factors in hospitalized diabetic patients: results of a cross-sectional study. Eur J Gastroenterol Hepatol 2008, 20:829-836.